{
    "root": "3e592db1-3d52-47f9-9201-c466053f467c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sucralfate",
    "value": "20241212",
    "ingredients": [
        {
            "name": "SUCRALFATE",
            "code": "XX73205DH5"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O"
        },
        {
            "name": "SORBIC ACID",
            "code": "X045WJ989B"
        },
        {
            "name": "BENZOIC ACID",
            "code": "8SKN0B0MIM"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "Sucralfate Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.",
    "contraindications": "Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 gram (10 mL) four times per day. Sucralfate Oral Suspension should be administered on an empty stomach.\n      \n\n \n                  Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after Sucralfate Oral Suspension.\n                  While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.\n                  \n                     Elderly. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see \n       \n \n  PRECAUTIONS \n        \n  \n   Geriatric Use\n                     ).\n      \n\n \n                  Call your doctor for medical advice about side effects. You may report side effects to Pharmaceutical Associates, Inc. at 1-800-845-8210 or FDA at 1-800-FDA-1088 or \n       \n \n  www.fda.gov/medwatch.",
    "warningsAndPrecautions": "Sucralfate Oral Suspension, 1 g/10 mL is a pink suspension with cherry flavor supplied in the following dosage forms:\n                  NDC 63739-193-72: 10 mL Unit Dose Cup\n                  NDC 63739-193-51: Case of 20, 10 mL Unit Dose Cups\n                  SHAKE WELL BEFORE USING. AVOID FREEZING.\n                  Store at controlled room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature].\n                  Rx Only\n                  \n                  \n                     Distributed By:\n                  \n                  McKesson Corporation \n                  dba SKY Packaging\n                  Memphis, TN 38141\n                  ISS. 10/2022",
    "adverseReactions": "Sucralfate Oral Suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients."
}